Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Neutrophil extracellular trap-related genes in PTCL: identification,… Lenalidomide · PMID 41772937 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source This study aimed to identify neutrophil extracellular trap-related genes (NET-RGs), explore their prognostic significan… | Hematology (Amsterdam, Netherlands) 2026-08-16 13:16:43 | Source |
| Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lym… Brentuximab Vedotin · PMID 42269084 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Blood advances 2026-08-16 13:16:40 | Source |
| Effectiveness and safety of brentuximab vedotin-containing regimen ve… Brentuximab Vedotin · PMID 42432844 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%.… | Hematology (Amsterdam, Netherlands) 2026-08-16 13:16:40 | Source |
| Role of radiotherapy in refractory/relapsed classical Hodgkin lymphom… Brentuximab Vedotin · PMID 42388465 | Cancer | Thérapie cellulaire | Publication | PubMed | Voir la publication source Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains a complex therapeutic challenge despite major advan… | Clinical and translational radiation oncology 2026-08-16 13:16:40 | Source |
| Acral lentiginous melanoma metastases to the vitreous masquerading as… TIME-NL — Timing of Immunotherapy in Melanoma · PMID 42254311 | Cancer | Ralentissement de la progression · Traitement symptomatique | Publication | PubMed | Voir la publication source Cutaneous melanoma is the most common malignancy to present with vitreous metastasis. This report describes a case of v… | American journal of ophthalmology case reports 2026-08-16 13:16:37 | Source |
| Advanced Metastatic Melanoma With C-KIT (CD117) Immunohistochemical E… TIME-NL — Timing of Immunotherapy in Melanoma · PMID 42482712 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Melanoma is an aggressive malignancy characterized by significant molecular heterogeneity and poor prognosis in advance… | Cureus 2026-08-16 13:16:37 | Source |
| Political determinants of melanoma: Global inequities in skin cancer… TIME-NL — Timing of Immunotherapy in Melanoma · PMID 42292071 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Melanoma outcomes differ across countries, income settings, and skin tones, reflecting not only variable environmental… | JAAD international 2026-08-16 13:16:37 | Source |
| Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childho… Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment · PMI… | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Endocrine disorders in survivors of childhood, adolescent, and young adult (CAYA) cancers are associated with substanti… | Endocrine reviews 2026-08-16 13:16:36 | Source |
| Poor bone health at the end of puberty in childhood cancer survivors. Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment · PMI… | Cancer | À vérifier | Publication | PubMed | Voir la publication source Although the survival rate following childhood cancer is >80%, late effects are a major concern. We aimed to determine… | Pediatric blood & cancer 2026-08-16 13:16:36 | Source |
| [Endocrine late-effects and bone mineral density after combined treat… Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment · PMI… | Cancer | À vérifier | Publication | PubMed | Voir la publication source The implementation of standardized protocols for combined treatment of cancer into clinical practice inevitably leads t… | Problemy endokrinologii 2026-08-16 13:16:36 | Source |
| AKR1C3 and CLIC3 mediate the comorbidity of diabetic foot ulcers and… Exemestane · PMID 42462461 | Cancer | Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Hypercholesterolemia (HCh) represents a prevalent comorbidity in patients with diabetic foot ulcers (DFUs), frequently… | Biochemical and biophysical research communications 2026-08-16 13:16:34 | Source |
| A phase II study of androgen receptor inhibition by darolutamide in c… Exemestane · PMID 42574969 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source To determine the efficacy and safety of darolutamide, exemestane, and leuprolide acetate in recurrent adult-type ovaria… | Gynecologic oncology 2026-08-16 13:16:34 | Source |
| Exemestane induces neurodevelopmental defects and behavioral diorder… Exemestane · PMID 42055200 | Cancer | Neuroprotection | Publication | PubMed | Voir la publication source Exemestane, a third-generation oral aromatase inhibitor used clinically for breast cancer treatment, may exhibit potent… | Comparative biochemistry and physiology. Toxicology &… 2026-08-16 13:16:34 | Source |
| Strangulated Ileus Caused by Clips Used for Closure of an Appendiceal… Computed Tomography · PMID 42436720 | Cancer | Traitement symptomatique | Publication | PubMed | Voir la publication source Perforation developing during endoscopic submucosal dissection (ESD) for colorectal lesions can necessitate halting of… | DEN open 2026-08-16 13:16:33 | Source |
| Successful Endoscopic Submucosal Dissection for Primary Esophageal Mu… Computed Tomography · PMID 42465713 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Primary esophageal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is extremely… | DEN open 2026-08-16 13:16:33 | Source |
| Transpapillary Placement of a Multihole Covered Metal Stent Using a 5… Chemotherapy · PMID 42548893 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Concurrent malignant biliary obstruction (MBO) and type I duodenal stenosis represent a technically demanding scenario,… | DEN open 2026-08-16 13:16:33 | Source |
| Alternative trials of recipient site vessel in maxillomandibular reco… Bone Scan · PMID 42000208 | Cancer | À vérifier | Publication | PubMed | Voir la publication source The objective of this study is to closely examine the preferred anastomoses of the superior thyroid artery, facial arte… | Injury 2026-08-16 13:16:32 | Source |
| Localisation and outcome of presumed thoracolumbar vertebral stress f… Bone Scan · PMID 41327941 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Stress fracture is an important cause of mortality and morbidity in racing Thoroughbreds. Nuclear scintigraphy is the i… | Equine veterinary journal 2026-08-16 13:16:32 | Source |
| Redefining bone metastasis imaging in breast cancer: whole body low-d… Bone Scan · PMID 42087716 | Cancer | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Skeletal scintigraphy is standard imaging to detect bone metastasis in breast cancer. Nuclear medicine facilities are l… | Nuclear medicine communications 2026-08-16 13:16:32 | Source |
| Brain-derived neurotrophic factor (BDNF) in neonatal blood: associati… Biospecimen Collection · PMID 42567895 | Cancer · Lupus · Sclérose en plaques · Cancer · Lupus | Ralentissement de la progression | Publication | PubMed | Voir la publication source Neurotrophins, including brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), have been associated with… | Pediatric research 2026-08-16 13:16:31 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||